Clinical Trials Browser

Leukemia, Lymphocytic, Chronic, B-Cell

NCT05044039 2026-02-02

Duvelisib Following Chimeric Antigen Receptor T-Cell Therapy

Phase 1 Active not recruiting

42 enrolled

LymphoidOther hematologic neoplasm

Lymphoma, Non-Hodgkin, Precursor Cell Lymphoblastic Leukemia-Lymphoma

NCT03961672 2026-01-05

Intermittent Duvelisib Dosing in Treating Patients With Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma

Phase 2 Active not recruiting

15 enrolled 13 charts

LymphoidOther hematologic neoplasm

Leukemia, Lymphocytic, Chronic, B-Cell

NCT04331119 2025-12-30

Duvelisib Maintenance After Autologous Stem Cell Transplant in T-Cell Lymphomas

Phase 2 Active not recruiting

17 enrolled

Lymphoid

Lymphoma, T-Cell

NCT07293403 2025-12-19

Duvelisib Maintenance for the Treatment of Peripheral T-Cell Lymphomas

Phase 2 Not yet recruiting

25 enrolled

Lymphoid

Lymphoma, T-Cell

NCT05065866 2025-12-04

Duvelisib in Combination With BMS-986345 in Lymphoid Malignancy

Phase 1 Completed

14 enrolled

LymphoidOther hematologic neoplasmPlasma cell

Hodgkin Disease, Leukemia, Lymphoid, Lymphoma, Non-Hodgkin, Neoplasms, Plasma Cell

NCT05010005 2025-12-03

A Study of Ruxolitinib and Duvelisib in People With Lymphoma

Phase 1 Recruiting

70 enrolled

LymphoidOther hematologic neoplasm

Recurrence, Leukemia, Prolymphocytic, T-Cell, Lymphoma, T-Cell, Leukemia, Large Granular Lymphocytic

NCT05057247 2025-10-31

Duvelisib Plus Docetaxel In Recurrent/Metastatic HNSCC

Phase 2 Completed

26 enrolled 23 charts

Head & Neck

Squamous Cell Carcinoma of Head and Neck, Head and Neck Neoplasms

NCT03534323 2025-08-14

Duvelisib and Venetoclax in Relapsed or Refractory CLL or SLL or RS

Phase 1/2 Active not recruiting

67 enrolled

LymphoidOther hematologic neoplasm

Leukemia, Lymphocytic, Chronic, B-Cell

NCT07001384 2025-08-14

A Study of Alectinib and Duvelisib in People With Anaplastic Lymphoma Kinase-Positive Anaplastic Large Cell Lymphoma (ALK+ALCL)

Phase 1 Recruiting

30 enrolled

Lymphoid

Lymphoma, Large-Cell, Anaplastic

NCT02783625 2025-06-03

Trial of Duvelisib in Combination With Either Romidepsin or Bortezomib in Relapsed/Refractory T-cell Lymphomas

Phase 1 Active not recruiting

114 enrolled

Lymphoid

Lymphoma, Lymphoma, T-Cell

NCT04890236 2025-01-20

Duvelisib Exposure to Enhance Immune Profiles of T Cells in Patients With Recurrent or Refractory Diffuse Large B-Cell Lymphoma, DEEP T CELLS Study

Phase EARLY_PHASE1 Completed

4 enrolled

Lymphoid

Lymphoma, Large B-Cell, Diffuse

NCT03892044 2024-05-02

Duvelisib and Nivolumab in Treating Patients With Richter Syndrome or Transformed Follicular Lymphoma

Phase 1 Completed

7 enrolled

LymphoidOther hematologic neoplasm

Leukemia, Lymphocytic, Chronic, B-Cell, Lymphoma, Large B-Cell, Diffuse

NCT05976997 2023-08-04

Prospective, Single Arm, Single Center Study of Duvelisib Combined With Chidamide in the Treatment of Newly Diagnosed Peripheral T-cell Lymphoma (PTCL)

Phase 2 Unknown

36 enrolled

Lymphoid

Lymphoma, T-Cell, Peripheral

NCT04836832 2022-06-07

Acalabrutinib and Duvelisib for the Treatment of Relapsed/Refractory Indolent Non-Hodgkin Lymphoma

Phase 1 Withdrawn

Lymphoid

Lymphoma, Follicular, Lymphoma, B-Cell, Marginal Zone

NCT01871675 2016-07-11

Study of IPI-145 in Combination With Rituximab or Bendamustine/Rituximab in Hematologic Malignancies

Phase 1 Completed

48 enrolled

LymphoidOther hematologic neoplasm

Lymphoma, Lymphoma, Non-Hodgkin, Recurrence, Leukemia, Lymphocytic, Chronic, B-Cell, Lymphoma, T-Cell, Hematologic Neoplasms

NCT02028039 2014-01-06

IPI-145 in Relapsed Refractory Acute Lymphoblastic Leukemia (ALL)

Phase 2 Withdrawn

LymphoidOther hematologic neoplasm

Burkitt Lymphoma, Leukemia, Precursor Cell Lymphoblastic Leukemia-Lymphoma

Clinical Trials

A Phase 1b/2 Study of IPI-145 Plus FCR in Previously Untreated, Younger Patients With CLL

Duvelisib Following Chimeric Antigen Receptor T-Cell Therapy

Intermittent Duvelisib Dosing in Treating Patients With Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma

Duvelisib Maintenance After Autologous Stem Cell Transplant in T-Cell Lymphomas

Duvelisib Maintenance for the Treatment of Peripheral T-Cell Lymphomas

Duvelisib in Combination With BMS-986345 in Lymphoid Malignancy

A Study of Ruxolitinib and Duvelisib in People With Lymphoma

Duvelisib Plus Docetaxel In Recurrent/Metastatic HNSCC

Duvelisib and Venetoclax in Relapsed or Refractory CLL or SLL or RS

A Study of Alectinib and Duvelisib in People With Anaplastic Lymphoma Kinase-Positive Anaplastic Large Cell Lymphoma (ALK+ALCL)

Trial of Duvelisib in Combination With Either Romidepsin or Bortezomib in Relapsed/Refractory T-cell Lymphomas

Duvelisib Exposure to Enhance Immune Profiles of T Cells in Patients With Recurrent or Refractory Diffuse Large B-Cell Lymphoma, DEEP T CELLS Study

Duvelisib and Nivolumab in Treating Patients With Richter Syndrome or Transformed Follicular Lymphoma

Prospective, Single Arm, Single Center Study of Duvelisib Combined With Chidamide in the Treatment of Newly Diagnosed Peripheral T-cell Lymphoma (PTCL)

Acalabrutinib and Duvelisib for the Treatment of Relapsed/Refractory Indolent Non-Hodgkin Lymphoma

Study of IPI-145 in Combination With Rituximab or Bendamustine/Rituximab in Hematologic Malignancies

IPI-145 in Relapsed Refractory Acute Lymphoblastic Leukemia (ALL)